drugset / Trial / NCT00504426
Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to examine the efficacy and safety of OPC-249 by once daily inhalation at 0 (placebo), 30, 60 or 120 IU for 4 weeks in patients with pain due to osteoporosis.
Timeline
- Start
- 2007-07
- Primary completion
- 2008-07
- Completion
- 2009-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | OPC-249 | Unknown | 30 iu | Inhaled |
| Comparator | OPC-249 | Unknown | 60 iu | Inhaled |
| Comparator | OPC-249 | Unknown | 90 iu | Inhaled |
| Comparator | OPC-249 | Unknown | 120 iu | Inhaled |